Signalling Defects and Disease 12 1

Total Page:16

File Type:pdf, Size:1020Kb

Load more

r r r Cell Signalling Biology Michael J. Berridge Module 12 Signalling Defects and Disease 12 1 Module 12 Signalling Defects and Disease Synopsis A large number of diseases are caused by defects in signalling pathways. The nature of these defects and how they are induced varies enormously. Pathogenic organisms and viruses, many of which can interfere with signalling events, can cause some of these defects. There are other diseases that can be traced to defects in the function of cell signalling pathways. The concept of signalsome remodelling and disease provides a framework for considering how defects in signalling pathways can result in disease. It is convenient to separate these defects into phenotypic remodelling of the signalsome and genotypic remodelling of the signalsome. Most of the serious diseases in humans, such as hypertension, heart disease, diabetes and many forms of mental illness, seem to arise from subtle phenotypic modifications of signalling pathways. Such phenotypic remodelling alters the behaviour of cells so that their normal functions are subverted, leading to disease. Since it has proved difficult to clearly establish this relationship between signalsome remodelling and disease, there has been relatively little progress in designing effective treatments. Genotypic modifications resulting from either somatic mutations or germline mutations have been somewhat easier to diagnose, but have also proved difficult to treat as witnessed by the failure of many of the gene therapy strategies. Clearly, there is an urgent need to understand more about all of these disease states in order to design better therapies. The enormous redundancy built into cell signalling mechanisms offers many opportunities for discovering new ways of correcting many disease states. The reversal of Ca2+-dependent neurodegeneration is an example where such a strategy could provide novel therapies for treating some of the major neural diseases in humans such as Alzheimer’s disease and Parkinson’s disease. Pathogenic organisms and viruses • Listeriosis is caused by Listeria monocytogenes,whichis A number of pathogenic organisms and viruses exert their a Gram-positive pathogen that survives in macrophages deleterious effects by modifying the signalling processes by escaping through the phagolysosome membrane. operating in specific cell types: • Peptic ulcers are caused by an excessive production of acid caused by infection of the stomach with Helicobac- • Bacillary dysentery is caused by Shigella flexneri,which ter pylori. acts by interfering with the PtdIns4,5P2 regulation of • Tuberculosis is an example where the pathogen (My- actin remodelling and is also able to activate the PtdIns cobacterium tuberculosis) survives by switching off the 3-kinase signalling pathway. A similar mechanism is em- phagosome maturation process that macrophages use to ployed by Salmonella enterica serotype Typhimurium. kill infectious organisms. • Cholera is caused by the Gram-negative bacterium Vi- brio cholerae, which secretes the cholera toxin (CT) that causes severe water loss, vomiting and muscle Bacillary dysentery cramps. CT activates the cyclic AMP signalling path- Shigella flexneri, which causes bacillary dysentery, modi- way (Module 2: Figure cyclic AMP signalling). fies some of the host cell signalling pathways to facilitate • Chlamydial diseases caused by Chlamydia trachomatis their entry and to boost their virulence. S. flexneri injects also survive by inhibiting the phagocytic processes of the host cell with an effector protein IpgD, which is a phos- macrophages. phoinositide phosphatase that hydrolyses PtdIns4,5P2 to PtdIns5P. Entry of the pathogen into the host is facilit- ated by the decline in the level of PtdIns4,5P2 because of the disruption in the normal PtdIns4,5P2 regulation Please cite as Berridge, M.J. (2014) Cell Signalling Biology; of actin remodelling. In addition, the PtdIns5P formed doi:10.1042/csb0001012 by the hydrolysis may also play a role by activating the C 2014 Portland Press Limited www.cellsignallingbiology.org Licensed copy. Copying is not permitted, except with prior permission and as allowed by law. r r r Cell Signalling Biology Michael J. Berridge Module 12 Signalling Defects and Disease 12 2 PtdIns5P signalling cassette, which can regulate a number ach by developing a number of adaptations that enables of host cell functions. In particular, PtdIns5P can activate it to cope with the highly acidic environment. The bac- the class IA PtdIns 3-kinase to activate the PtdIns 3-k- terium attaches itself to the surface of the epithelial cells inase signalling pathway, and one effect of this will be through a variety of adhesion proteins. Marshall and War- to promote host survival by preventing apoptosis. The ren received the Nobel Prize in Physiology and Medicine hormonal modulation of apoptosis is strongly regulated in 2005 for uncovering the link between H. pylori and by the PtdIns 3-kinase signalling pathway. the onset of peptic ulcer disease. It is now known that most duodenal ulcers and approximately 70% of gast- Cholera ric ulcers are caused by this bacterial infection. In addi- tion, most stomach cancers are associated with infections Cholera is characterized by severe water loss, vomiting and of H. pylori. Eradication of the infection with drugs has muscle cramps. It is caused by infection with the Gram- proved to be a highly effective means of curing peptic negative bacterium Vibrio cholerae, which secretes chol- ulcers. era toxin (CT) that can activate the cyclic AMP signalling H. pylori has an elaborate ’nano-syringe’ that it uses pathway (Module 2: Figure cyclic AMP signalling). CT is to inject proteins such as the cytoxin-associated gene A composed of a catalytic A subunit and five B subunits. The (CagA) directly into the host cell (Module 12: Figure H latter attach the toxin to the surface of the cell, where they pylori nano-syringe). At the tip of this syringe is the pro- function as membrane-penetration subunits that inject the tein cytotoxin-associated gene A ligand (CagL) that has catalytic subunit into the cell. The toxin interacts with a RGD motifs that enables it to bind to the α5β1 integ- GM1 ganglioside on the cell surface of intestinal epithelial rin complex found on the surface of the host cell surface cells, and this enables the A subunit to enter the cell, where (Module 1: Figure integrin receptor). The CagL thus func- it stimulates fluid secretion by activating cyclic AMP form- tions as a stimulus to activate integrin signalling that then ation (Module 7: Figure intestinal secretion). The catalytic creates the conditions for both the injection and the ac- A subunit catalyses the transfer of ADP-ribose from NAD tivation of the oncoprotein cytotoxin-associated gene A to an arginine group on the α subunit of GS (Module 2: (CagA). Figure cyclic AMP signalling). This ADP ribosylation in- Once it enters the epithelial cells, CagA interacts with hibits the ability of GS to hydrolyse GTP, which means resident regulatory proteins to alter both cell structure that this G protein is locked in its active configuration and and cell fate. It disrupts tight junctions by associating thus maintains a persistent activation of cyclic AMP and with proteins such as ZO-1, JAM and the partitioning- intestinal secretion. defective 1 (PAR1)/microtubule affinity-regulating kinase (MARK) family of serine-threonine kinases. The result- Listeriosis ing junctional and polarity defects result in ulcerations, After bacteria have been engulfed, they are normally des- inflammation (gastritis) and can lead to gastric carcino- troyed by a process of phagosome maturation.Inthe genesis. An increase in proliferation is facilitated by the case of the Gram-positive pathogen Listeria monocyto- ability of CagA to induce various signalling pathways to genes, however, the pathogen survives the attention of stimulate transcription factors such as NF-κB, NFAT and macrophages by escaping through the membrane of the SRF. phagolysosome to enter the cytoplasm where they can Just how H. pylori increases in acid secretion that causes replicate and then go on to infect other cells. The bacterial ulcers is still being worked out. There is increasing evid- virulence factor listeriolysin O (LLO) seems to be critical ence to show that the bacterium somehow alters the activ- in that it can oligomerize to form pores in host mem- ity of the cells that regulate the release of gastrin. For branes. One of the functions of these pores is to provide example, there is an increase in the resting rate of gastrin a leak pathway for proteins that prevents the acidification release by the G cells located in the antrum of the stomach of the phagosome that is necessary for it to fuse with the (Module 7: Figure stomach structure). In addition, there lysosomes. In order to lyse the phagosomal membrane to is a decrease in the activity of the D cells that release so- gain access to the cytoplasm, LLO must be reduced and matostatin, which is part of a negative-feedback loop that this is done by making use of the γ-interferon-inducible operates in the control of parietal cell secretion (Module 7: lysosome thiol reductase (GILT), which is a host enzyme Figure HCl secretion). located in the phagosome. The phagosome membrane has NADPH oxidase and nitrogen oxide synthase that gener- Tuberculosis ate the antimicrobial agents reactive oxygen species (ROS) Mycobacterium tuberculosis evades the rapid inflammatory and reactive nitrogen species (RNS) respectively. GILT responses used to attack foreign pathogens as part of the neutralizes the action of ROS and RNS thus enabling Lis- innate immune system. Once such pathogens are taken up teria to escape into the cytoplasm. into the phagosome, they are killed when hydrolytic en- zymes are added during phagosome maturation (Module Peptic ulcers 4: Figure phagosome maturation). M. tuberculosis has de- Peptic ulcers are caused by an excessive production of acid veloped various mechanisms to manipulate the host’s sig- that damages the gastric mucosa. One of the main causes of nalling pathways enabling it to survive and proliferate.
Recommended publications
  • FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer

    FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer

    FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating TGFβ/Smad-Independent Pathways in Gastric Cancer Guodong Cao First Aliated Hospital of Anhui Medical University Pengping Li Hangzhou Xiaoshan No 1 People's Hospital Qiang Sun Xuzhou Medical University Sihan Chen First Aliated Hospital of Anhui Medical University Xin Xu First Aliated Hospital of Anhui Medical University Xiaobo He First Aliated Hospital of Anhui Medical University Zhenyu Wang Hangzhou Xiaoshan No 1 People's Hospital Peng Chen First Aliated Hospital of Anhui Medical University Maoming Xiong ( [email protected] ) First Aliated Hospital of Anhui Medical University Bo Chen First Aliated Hospital of Anhui Medical University Research Keywords: EMT, Chemotherapy resistance, FHL3, Ubiquitination, Gastric cancer Posted Date: October 9th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-87249/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. ReLoaadd iFngu l[Ml LaitchJeanxs]/ejax/output/CommonHTML/jax.js Page 1/28 Loading [MathJax]/jax/output/CommonHTML/jax.js Page 2/28 Abstract Background: Gastric cancer presents high risk of metastasis and chemotherapy resistance. Hence, the mechanistic understanding of the tumor metastasis and chemotherapy resistance is quietly important. Methods: TCGA database and clinical samples are used for exploring the role of FHL3 in disease progression and prognosis. The roles of FHL3 in metastasis and chemotherapy resistance are explored in vitro and in vivo by siRNA or shRNA treatment. Finally, we explore the FHL3-mediated EMT and chemotherapy resistance. Results: mRNA and protein level of FHL3 is signicantly up-regulated in gastric cancer tissues when compares with it in adjacent tissue.
  • In Vivo Studies Using the Classical Mouse Diversity Panel

    In Vivo Studies Using the Classical Mouse Diversity Panel

    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
  • Pnas11138correction 14002..14003

    Pnas11138correction 14002..14003

    Corrections MEDICAL SCIENCES Correction for “Regulation of bone remodeling by vasopressin New, Alberta Zallone, and Mone Zaidi, which appeared in issue 46, explains the bone loss in hyponatremia,” by Roberto Tamma, November 12, 2013, of Proc Natl Acad Sci USA (110:18644–18649; Li Sun, Concetta Cuscito, Ping Lu, Michelangelo Corcelli, first published October 28, 2013; 10.1073/pnas.1318257110). Jianhua Li, Graziana Colaianni, Surinder S. Moonga, Adriana The authors note that Fig. 1 appeared incorrectly. The cor- Di Benedetto, Maria Grano, Silvia Colucci, Tony Yuen, Maria I. rected figure and its legend appear below. Fig. 1. Bone cells express Avprs. Immunofluorescence micrographs (A) and Western immunoblotting (B) show the expression of Avpr1α in osteoblasts and osteoclasts, and as a function of osteoblast (mineralization) and osteoclast (with Rankl) differentiation. The expression of Avp (ligand) and Avpr1α (receptor) in osteoblasts is regulated by 17β-estradiol, as determined by quantitative PCR (C) and Western immunoblotting (D). (Magnification: A,63×.) Because Avp is a small peptide, its precursor neurophysin II is measured. Statistics: Student t test, P values shown compared with 0 h. Stimulation of Erk phosphorylation − (p-Erk) as a function of total Erk (t-Erk) by Avp (10 8 M) in osteoclast precursors (preosteoclasts), osteoclasts (OC), and osteoblasts establishes functionality of − the Avpr1α in the presence or absence of the receptor inhibitor SR49059 (10 8 M) (E). Western immunoblotting showing the expression of Avpr2 in pre- −/− osteoclasts, OCs (F), and osteoblasts (G) isolated from Avpr1α mice, as well as in MC3T3.E1 osteoblast precursors (G). Functionality of Avpr2 was confirmed −/− by the demonstration that cells from Avpr1α mice remained responsive to AVP in reducing the expression of osteoblast differentiation genes, namely Runx2, Osx, Bsp, Atf4, Opn, and Osteocalcin (quantitative PCR, P values shown) (H).
  • Sat-196 How to Estimate Glomerular Filtration Rate

    Sat-196 How to Estimate Glomerular Filtration Rate

    ISN WCN 2019 ABSTRACTS 13 (28%) patients had CKD stage 3. 6/13 had low predicted risk of Nephrology, Melbourne, Australia, 8Austin Hospital, Nephrology, Heidel- berg, Australia, 9Monash Childrens Hospital, Nephrology, Australia, progression at 5 years of whom 4/6 progressed unexpectedly. 1/13 was 10 identified as having high risk at 5 years and that 1 patient progressed to Melbourne Genomics Health Alliance, Victorian Clinical Genetics Service, Melbourne, Australia, 11Australian Genomic Health Alliance, KidGen Renal CKD5D/T. Genetics Flagship, Australia, Australia, 12Royal Childrens Hospital, 6/18 CKD 3/4 patients with predicted low risk progressed to CKD5D/ Nephrology, Melbourne, Australia T unexpectedly. 1/6 had emergency abdominal surgery, 1/6 patient had Introduction: Genomic technologies enable the rapid and cost-effective unexplained rapid progression and 4/6 had acute upper gastro-intes- fi tinal haemorrhage causing terminal decline of kidney function. sequencing of DNA and have demonstrated a de nitive diagnosis in Conclusions: The number of patients analysed was small. The 8-vari- several patient groups. The clinical utility of whole exome sequencing able equation accurately predicted high risk of progression to CKD5D/T (WES) in a kidney disease cohort is not yet well established. We in 7/9 CKD3/4 patients. describe the patient characteristics and diagnostic yield of a cohort of Conversely, 6/18 patients with predicted low risk progressed to 200 patients with suspected genetic kidney disease referred for WES via CKD5D/T. Acute medical events including upper gastro-intestinal bleed a multidisciplinary renal genetics clinic. Methods: accounted for most instances of unexpected progression. 200 sequential patients were recruited into a prospective observational cohort study through five tertiary academic centres in Victoria, Australia.
  • Benefits of Exome Sequencing in Children with Suspected Isolated

    Benefits of Exome Sequencing in Children with Suspected Isolated

    G C A T T A C G G C A T genes Article Benefits of Exome Sequencing in Children with Suspected Isolated Hearing Loss Roxane Van Heurck 1, Maria Teresa Carminho-Rodrigues 1, Emmanuelle Ranza 1, Caterina Stafuzza 2, Lina Quteineh 1, Corinne Gehrig 1, Eva Hammar 1, Michel Guipponi 1, Marc Abramowicz 1, Pascal Senn 2 , Nils Guinand 2, Helene Cao-Van 2 and Ariane Paoloni-Giacobino 1,* 1 Division of Genetic Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; [email protected] (R.V.H.); [email protected] (M.T.C.-R.); [email protected] (E.R.); [email protected] (L.Q.); [email protected] (C.G.); [email protected] (E.H.); [email protected] (M.G.); [email protected] (M.A.) 2 Ear-Nose-Throat/Head and Neck Surgery Division, Geneva University Hospitals, 1205 Geneva, Switzerland; [email protected] (C.S.); [email protected] (P.S.); [email protected] (N.G.); [email protected] (H.C.-V.) * Correspondence: [email protected] Abstract: Purpose: Hearing loss is characterized by an extensive genetic heterogeneity and remains a common disorder in children. Molecular diagnosis is of particular benefit in children, and permits the early identification of clinically-unrecognized hearing loss syndromes, which permits effective clinical management and follow-up, including genetic counselling. Methods: We performed whole-exome Citation: Van Heurck, R.; sequencing with the analysis of a panel of 189 genes associated with hearing loss in a prospective Carminho-Rodrigues, M.T.; Ranza, E.; cohort of 61 children and 9 adults presenting mainly with isolated hearing loss.
  • Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    BMB Rep. 2015; 48(12): 647-654 BMB www.bmbreports.org Reports Invited Mini Review Primary cilia in energy balance signaling and metabolic disorder Hankyu Lee, Jieun Song, Joo Hyun Jung & Hyuk Wan Ko* College of Pharmacy, Dongguk University, Goyang 10326, Korea Energy homeostasis in our body system is maintained by bal- complex, due to many confounding genetics and environ- ancing the intake and expenditure of energy. Excessive accu- mental factors equivocally affecting the progress of the disease. mulation of fat by disrupting the balance system causes over- Moreover, metabolic disorders are interrelated diseases exem- weight and obesity, which are increasingly becoming global plified by the association of obesity with insulin resistance, health concerns. Understanding the pathogenesis of obesity fo- leading to development of type II diabetes (2). Genetic factors cused on studying the genes related to familial types of for obesity are poorly understood, and recent progress by ge- obesity. Recently, a rare human genetic disorder, ciliopathy, nome-wide association studies support the notion of polygenic links the role for genes regulating structure and function of a features of obesity which suggests that multiple genes, tissues cellular organelle, the primary cilium, to metabolic disorder, and pathways contribute to the disease (3, 4). Intriguing subset obesity and type II diabetes. Primary cilia are microtubule of genes associated with obesity cause a dysfunction of pri- based hair-like membranous structures, lacking motility and mary cilia, which results in a rare pleiotropic human disorder functions such as sensing the environmental cues, and trans- called ciliopathy (5, 6). Primary cilia are microtubule based ducing extracellular signals within the cells.
  • Cooperation to Amplify Gene-Dosage-Imbalance Effects

    Cooperation to Amplify Gene-Dosage-Imbalance Effects

    Update TRENDS in Molecular Medicine Vol.12 No.10 Research Focus Cooperation to amplify gene-dosage-imbalance effects Susana de la Luna1 and Xavier Estivill2 1 ICREA and Gene Function Group, Genes and Disease Program, Center for Genomic Regulation-CRG, 08003-Barcelona, Spain 2 Genetic Causes of Disease Group, Genes and Disease Program, Center for Genomic Regulation-CRG and Pompeu Fabra University, Barcelona Biomedical Research Park, 08003-Barcelona, Spain Trisomy 21, also known as Down syndrome (DS), is a From gene-dosage imbalance to pathology complex developmental disorder that affects many ThepresenceofanextracopyofHSA21 genes predicts an organs, including the brain, heart, skeleton and increased expression of 1.5-fold at the RNA level for immune system. A working hypothesis for understand- those genes in trisomy. Experiments in which this effect ing the consequences of trisomy 21 is that the over- has been evaluated indicate that this is indeed the case expression of certain genes on chromosome 21, alone for most HSA21 genes in DS samples and for their or in cooperation, is responsible for the clinical features orthologs in mouse trisomic models [3].Inthesimplest of DS. There is now compelling evidence that the scenario, the overexpression of one specific gene would protein products of two genes on chromosome 21, lead to the disturbance of a biological process and, as a Down syndrome candidate region 1 (DSCR1)and result, a single gene would be responsible for each patho- dual-specificity tyrosine-(Y)-phosphorylation regulated logical feature of DS. However, it is more probable that kinase 1A (DYRK1A), interact functionally, and that the overexpression of several of the 250 HSA21 genes their increased dosage cooperatively leads to dysregu- would contribute to alter a functional pathway in a lation of the signaling pathways that are controlled by specific cell at a specific time.
  • Table 2. Significant

    Table 2. Significant

    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
  • Dissertationes Medicinae Universitatis Tartuensis 178

    Dissertationes Medicinae Universitatis Tartuensis 178

    DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 178 DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 178 RITA TEEK The genetic causes of early onset hearing loss in Estonian children Department of Paediatrics, University of Tartu, Tartu, Estonia Dissertation is accepted for commencement of the degree of Doctor of Medical Sciences on September 22, 2010 by the Council of the Faculty of Medicine, University of Tartu, Estonia. Supervisors: Professor Katrin Õunap, MD, PhD, Department of Paediatrics, University of Tartu, Tartu, Estonia The Late Professor Mart Kull, MD, PhD, Department of Oto-Rhino-Laryngology, University of Tartu, Tartu, Estonia (2005–2008) Reviewers: Assistant Professor Gunnar Tasa, MD, PhD, Department of General and Molecular Pathology, University of Tartu, Tartu, Estonia Assistant Professor Oivi Uibo, MD, PhD, Department of Paediatrics, University of Tartu, Tartu, Estonia Opponent: Professor Lisbeth Tranebjærg, MD, PhD, Department of Audiology, H:S Bispebjerg Hospital, and Wilhelm Johannsen Centre of Functional Genomics Institute of Cellular and Molecular Medicine, ICMM, University of Copenhagen, The Panum Institute, Denmark Commencement: November 24, 2010 ISSN 1024–395x ISBN 978–9949–19–478–0 (trükis) ISBN 978–9949–19–479–7 (PDF) Autoriõigus: Rita Teek, 2010 Tartu Ülikooli Kirjastus www.tyk.ee Tellimuse nr. 570 To my patients and their families CONTENTS LIST OF ORIGINAL PUBLICATIONS ...................................................... 9 ABBREVIATIONS OF HEARING LOSS STUDY GROUPS AND PATIENTS ....................................................................................................
  • RCAN2 Isoform 2 Recombinant Protein Cat

    RCAN2 Isoform 2 Recombinant Protein Cat

    RCAN2 Isoform 2 Recombinant Protein Cat. No.: 95-114 RCAN2 Isoform 2 Recombinant Protein Specifications SPECIES: Mouse SOURCE SPECIES: E. coli SEQUENCE: aa 2 - 197 FUSION TAG: Fusion Partner: C-terminal His-tag TESTED APPLICATIONS: ELISA, WB APPLICATIONS: This recombinant protein can be used for WB and ELISA. For research use only. PREDICTED MOLECULAR 26 kDa (Calculated) WEIGHT: Properties PURITY: ~95% PHYSICAL STATE: Liquid 100mM sodium phosphate, 10mM Tris, 500mM NaCl, 25 mM imidazole, 2mM MgCl2, 10% BUFFER: gycerol Store in working aliquots at -70˚C. Avoid freeze/thaw cycles. When working with proteins STORAGE CONDITIONS: care should be taken to keep recombinant protein at a cool and stable temperature. September 29, 2021 1 https://www.prosci-inc.com/rcan2-isoform-2-recombinant-protein-95-114.html Additional Info OFFICIAL SYMBOL: Rcan2 RCAN2 Antibody: Csp2, MCIP2, ZAKI-4, Dscr1l1, Zaki4, Calcipressin-2, Calcineurin inhibitory ALTERNATE NAMES: protein ZAKI-4 ACCESSION NO.: AAH62141 PROTEIN GI NO.: 38328420 GENE ID: 53901 Background and References Regulator of calcineurin 2 (RCAN2), also known as ZAKI4 and DSCR1L1, is expressed as two isoforms differing at their N-terminus. The longer of the two (isoform 1) is expressed exclusively in the brain, while isoform 2 is ubiquitously expressed, with highest expression in brain, heart, and muscle (1,2). Both isoforms bind to the catalytic subunit of calcineurin, a Ca++-dependent protein phosphatase involved in several neuronal functions, though BACKGROUND: their C-terminal region and inhibit calcineurin’s activity (3). Unlike isoform 1 of RCAN2, the expression of the second isoform is not induced by the thyroid hormone T3 (3).
  • The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility

    The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice release channel important in LEL function, affects bladder −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. physiology. Here, we investigated this phenomenon further by exploring an un- The lower urinary tract (LUT) is composed of the urinary conventional role for TRPML1 channels in the regulation of Ca2+-signal- bladder and urethra—structures that serve the simple, reciprocal ing activity and contractility in bladder and urethral smooth muscle cells functions of storing and voiding urine (15).
  • Emerging Roles for Multifunctional Ion Channel Auxiliary Subunits in Cancer T ⁎ Alexander S

    Emerging Roles for Multifunctional Ion Channel Auxiliary Subunits in Cancer T ⁎ Alexander S

    Cell Calcium 80 (2019) 125–140 Contents lists available at ScienceDirect Cell Calcium journal homepage: www.elsevier.com/locate/ceca Emerging roles for multifunctional ion channel auxiliary subunits in cancer T ⁎ Alexander S. Hawortha,b, William J. Brackenburya,b, a Department of Biology, University of York, Heslington, York, YO10 5DD, UK b York Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, UK ARTICLE INFO ABSTRACT Keywords: Several superfamilies of plasma membrane channels which regulate transmembrane ion flux have also been Auxiliary subunit shown to regulate a multitude of cellular processes, including proliferation and migration. Ion channels are Cancer typically multimeric complexes consisting of conducting subunits and auxiliary, non-conducting subunits. Calcium channel Auxiliary subunits modulate the function of conducting subunits and have putative non-conducting roles, further Chloride channel expanding the repertoire of cellular processes governed by ion channel complexes to processes such as trans- Potassium channel cellular adhesion and gene transcription. Given this expansive influence of ion channels on cellular behaviour it Sodium channel is perhaps no surprise that aberrant ion channel expression is a common occurrence in cancer. This review will − focus on the conducting and non-conducting roles of the auxiliary subunits of various Ca2+,K+,Na+ and Cl channels and the burgeoning evidence linking such auxiliary subunits to cancer. Several subunits are upregu- lated (e.g. Cavβ,Cavγ) and downregulated (e.g. Kvβ) in cancer, while other subunits have been functionally implicated as oncogenes (e.g. Navβ1,Cavα2δ1) and tumour suppressor genes (e.g. CLCA2, KCNE2, BKγ1) based on in vivo studies. The strengthening link between ion channel auxiliary subunits and cancer has exposed these subunits as potential biomarkers and therapeutic targets.